MKI67 and neoplasm: Figures 7E, S6H, and S6I show that combined Braf/PI3K inhibition elicited potent growth inhibition in both models. Immunohistochemical staining revealed that proliferation was substantially inhibited in the PLX4720/GDC0941-treated group, with only few Ki67-positive cells being detectable in regressed tumor masses (Figure S6I).